

Antiphospholipase A₂ Receptor Antibody Titer and Subclass in Idiopathic Membranous Nephropathy

Julia M. Hofstra,* Hanna Debiec,^{†‡§} Colin D. Short,^{||} Timotheé Pellé,^{†‡§} Robert Kleta,[¶] Peter W. Mathieson,** Pierre Ronco,^{†‡§} Paul E. Brenchley,^{††} and Jack F. Wetzels*

*Department of Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; [†]Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche_S702, Paris, France; [‡]Université Pierre et Marie Curie, University of Paris 6, Paris, France; [§]Assistance Publique-Hôpitaux de Paris, Department of Nephrology, Tenon Hospital, Paris, France; ^{||}Department of Renal Medicine, Manchester Royal Infirmary, Manchester, United Kingdom; [¶]Centre for Nephrology, University College London, London, United Kingdom; **Academic Renal Unit, University of Bristol, Bristol, United Kingdom; and ^{††}School of Biomedicine, University of Manchester, Manchester, United Kingdom

ABSTRACT

The phospholipase A₂ receptor (PLA₂R) is the major target antigen in idiopathic membranous nephropathy. The technique for measuring antibodies against PLA₂R and the relationship between antibody titer and clinical characteristics are not well established. Here, we measured anti-PLA₂R (aPLA₂R) antibody titer and subclass in a well defined cohort of 117 Caucasian patients with idiopathic membranous nephropathy and nephrotic-range proteinuria using both indirect immunofluorescence testing (IIFT) and ELISA. We assessed agreement between tests and correlated antibody titer with clinical baseline parameters and outcome. In this cohort, aPLA₂R antibodies were positive in 74% and 72% of patients using IIFT and ELISA, respectively. Concordance between both tests was excellent (94% agreement, $\kappa=0.85$). Among 82 aPLA₂R-positive patients, antibody titer significantly correlated with baseline proteinuria ($P=0.02$). Spontaneous remissions occurred significantly less frequently among patients with high antibody titers (38% versus 4% in the lowest and highest tertiles, respectively; $P<0.01$). IgG4 was the dominant subclass in the majority of patients. Titers of IgG4, but not IgG1 or IgG3, significantly correlated with the occurrence of spontaneous remission ($P=0.03$). In summary, these data show high agreement between IIFT and ELISA assessments of aPLA₂R antibody titer and highlight the pathogenetic role of these antibodies, especially the IgG4 subclass, given the observed relationships between aPLA₂R titer, baseline proteinuria, and outcome.

J Am Soc Nephrol 23: 1735–1743, 2012. doi: 10.1681/ASN.2012030242

Membranous nephropathy (MN) is the leading cause of nephrotic syndrome in the adult Caucasian population, with 40%–50% of untreated patients progressing to ESRD.^{1,2} In one-third of patients, MN is caused by an underlying disease, such as a malignancy, infection, or systemic disease. Until recently, no underlying cause could be identified in two-thirds of patients, and in these patients, the disease was considered to be idiopathic (iMN).³ However, in 2009, the work by Beck *et al.*⁴ discussed the discovery of antibodies against the M-type phospholipase A₂ receptor (PLA₂R), a membrane glycoprotein located on the podocyte, in 70% of patients with iMN. This finding, thus, provided

evidence that iMN is an autoimmune disease. The important role of PLA₂R in the pathogenesis of iMN was also supported by the highly significant

Received March 7, 2012. Accepted June 27, 2012.

J.M.H., H.D., P.E.B., and J.F.W. contributed equally to this work.

Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Dr. Julia M. Hofstra, Radboud University Nijmegen Medical Centre, Department of Nephrology, 464, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Email: j.hofstra@nier.umcn.nl

Copyright © 2012 by the American Society of Nephrology

association between single nucleotide polymorphisms in the PLA₂R gene and the development of iMN.⁵

Meanwhile, several studies have evaluated anti-PLA₂R antibodies (aPLA₂R) in patients with iMN. These studies have confirmed that aPLA₂R antibodies are present in 60%–80% of patients with iMN. Some studies even reported an association between antibody titer and clinical characteristics, such as proteinuria,⁶ time to remission,⁷ and time between change in antibody titer and development of a remission and relapse.^{8,9} However, it is difficult to draw firm conclusions, because these studies were limited by small sample size and/or their cross-sectional nature. Moreover, some studies are not comparable because of the use of different techniques to detect the aPLA₂R antibodies (Western blotting and indirect immunofluorescence staining [IIFT]). There is also debate on the role of antibody subclass. Although most studies agree that IgG4 is the predominant subclass, antibodies of the IgG1 and IgG3 subclasses are often found.

The purpose of the current study was to evaluate aPLA₂R in a well defined and phenotyped cohort of iMN patients. To this end, members of our consortium have validated a commercially available IIFT test for the detection of aPLA₂R¹⁰ and developed an ELISA assay, which allows rapid and simple quantification of aPLA₂R levels.¹¹ Specifically, we examined concordance between the IIFT and ELISA tests in detecting aPLA₂R and assessed the different IgG antibody subclasses. We also studied correlations between presence of aPLA₂R, antibody titers, and subclass on the one hand and clinical parameters, such as baseline proteinuria and long-term outcome, on the other hand.

RESULTS

IIFT Versus ELISA Test for aPLA₂R

Our cohort (combined Dutch, French, and Manchester) included 117 patients with iMN (91 male and 26 female). Baseline characteristics are presented in Table 1. Typically, the majority of patients was male and middle-aged at time of diagnosis. Median serum creatinine was 95 μmol/L (range=51–320 μmol/L), and median proteinuria was 10.2 g/d (range=3.6–37.9 g/d). With the




Figure 1. Correlation between anti-PLA₂R antibody levels measured with IIFT (titers: 1/10 to 1/3200) and ELISA (units per milliliter) techniques. There is a significant correlation ($r=0.868$, $P<0.01$), but large overlap.

IIFT test, aPLA₂R antibodies were positive in 74% of patients compared with 72% of patients with the ELISA test. In seven (6%) patients, there was a discrepancy between both tests; two patients with negative staining in IIFT had positive ELISA titers, whereas five patients with positive IIFT staining were negative according to the ELISA. Thus, overall agreement between both tests was 94%, with a κ measure of agreement of 0.85.

In the cohort of 117 patients, aPLA₂R titers assessed by IIFT (dilutions of 1/10–1/3200) and ELISA (units per milliliter) were compared. Although there was a good correlation between titers of IIFT and ELISA ($r=0.868$, $P<0.01$), there was a large overlap between IIFT and ELISA titers (Figure 1).

Correlation with Baseline Parameters

We first assessed differences between aPLA₂R-positive and -negative patients. For this analysis, we only included the patients with concordant results in both IIFT and ELISA tests. Baseline characteristics did not significantly differ between aPLA₂R-positive and -negative patients (Table 2). For comparison,

Table 1. Baseline characteristics (n=117)

| | All (n=117) | Paris (n=20) | Nijmegen (n=77) | Manchester (n=20) |
|--|-----------------|----------------|-----------------|-------------------|
| Sex (male/female) | 91/26 | 13/7 | 64/13 | 14/6 |
| Age at diagnosis (yr) | 51±16 | 54±19 | 51±16 | 47±11 |
| Serum creatinine (μmol/L) | 95 (51–320) | 97 (61–259) | 95 (51–320) | 91 (60–261) |
| Serum albumin (g/L) | 22.5±6.3 | 17.3±7.0 | 23.4±5.7 | 24.8±4.6 |
| Proteinuria (g/d) | 10.2 (3.6–37.9) | 9.0 (4.1–24.0) | 11.0 (3.6–37.9) | 9.2 (3.8–20.1) |
| eGFR (ml/min per 1.73 m ²) | 73±27 | 69±25 | 73±28 | 77±26 |
| Interval Bx serum sample (mo) | 2 (–2 to 6) | 0 | 2 (0–6) | 1 (–2 to 5) |
| Follow-up (mo) | 54 (2–277) | 38 (9–104) | 56 (2–148) | 85 (4–277) |

In the French cohort, all serum samples were collected at time of renal biopsy. One patient was from a non-Manchester UK cohort.⁵ Data are mean ± SD or median (range). eGFR was calculated using the MDRD formula. Bx, renal biopsy.

Table 2. Baseline characteristics in aPLA₂R-positive and -negative patients

| | aPLA ₂ R+ (n=82) | aPLA ₂ R- (n=28) | aPLA ₂ R+/- (n=7) |
|--|-----------------------------|-----------------------------|------------------------------|
| Sex (male/female) | 61/21 | 24/4 | 6/1 |
| Age at diagnosis (yr) | 50±16 | 51±17 | 58±19 |
| Serum creatinine (μmol/L) | 94 (51–320) | 97 (58–280) | 97 (70–187) |
| Serum albumin (g/L) | 23.0±5.5 | 21.9±7.5 | 18.0 (9–32) |
| Proteinuria (g/d) | 9.9 (3.6–37.9) | 10.5 (4.2–20.0) | 5.7 (4.2–17.6) |
| eGFR (ml/min per 1.73 m ²) | 73±27 | 75±27 | 69±22 |
| Interval Bx serum sample (mo) | 2 (-2 to 6) | 2 (0–6) | 0 (0–5) |

There were no significant differences between groups. Data are mean ± SD or median (range). eGFR was calculated using the MDRD formula. aPLA₂R+, patients positive in both IIFT and ELISA tests; aPLA₂R-, patients negative in both tests (n=28); aPLA₂R+/-, discrepancy in antibody status between the two tests (n=7); Bx, renal biopsy.

characteristics of the discordant patients are provided in Table 2. In a sensitivity analysis, when adding the discordant patients to either the positive or negative cohorts, no differences between aPLA₂R-positive and -negative patients were observed.

We next assessed if antibody titers correlated with baseline characteristics. In aPLA₂R-positive patients, antibody titer measured by ELISA weakly correlated with baseline proteinuria (n=82; r=0.259, P=0.02). Using the IIFT assay, the correlation was not significant (n=82; r=0.158, P=0.16).

Antibody titer may not reflect antibody production, because IgG will be lost in the urine. Therefore, we reanalyzed the data and adjusted the titers for fractional IgG excretion (as representative of urinary loss of antibodies) using the Dutch cohort (Concise Methods). In this cohort, absolute ELISA aPLA₂R titers correlated with baseline proteinuria, and the strength of correlation substantially increased after adjustment (n=52; r=0.347, P=0.01 without adjustment; r=0.679, P<0.01 after adjustment) (Figure 2). In the Dutch cohort, conclusions were similar when using IIFT titer (n=52; r=0.297, P=0.03 without adjustment; r=0.680, P<0.01 with adjustment) (Supplemental Figure 1). Of note, the adjusted titers also correlated with baseline serum creatinine concentration (ELISA, r=0.479 with P<0.01; IIFT, r=0.487 with P<0.01) and baseline eGFR (ELISA, r=-0.482 with P<0.01; IIFT, r=-0.455 with P<0.01).

IgG Subclass Measurements

IgG subclasses were measured qualitatively by IIFT. The subclasses were present in 56% (IgG1), 4% (IgG2), 53% (IgG3), and 69% (IgG4) of all iMN patients. The presence of IgG4 correlated best with antibody positivity as established with the standard IIFT (r=0.880, P<0.01). In 11 of 87 (13%) aPLA₂R-positive patients, only IgG4 subclass antibodies were present. However, in 6 of 87 (7%) patients with a positive overall IIFT test, the subclass IgG4 test was negative. In all these patients, both IgG1 and IgG3 staining were positive.

We also quantitatively measured IgG subclasses with subtype-specific ELISA tests. The different subclasses were detectable above the normal threshold in 54%, 34%, 67%, and 74% of all patients for IgG1, IgG2, IgG3, and IgG4, respectively. Again, the presence of IgG4 correlated best with antibody positivity as defined by the total IgG ELISA (r=0.761, P<0.01). In




Figure 2. Correlation between anti-PLA₂R levels measured with an ELISA technique and proteinuria in patients of the Dutch cohort. (A) Unadjusted analysis. (B) Anti-PLA₂R levels adjusted for fractional excretion of IgG.




Figure 3. Correlation between IgG4 anti-PLA₂R antibody levels and total IgG anti-PLA₂R (ELISA technique). IgG4 antibodies and total IgG antibodies were quantitated (see Concise Methods). There is a significant correlation ($r=0.668$, $P<0.01$).

addition, in aPLA₂R-positive patients, the level of aPLA₂R-IgG4 (in nanograms per milliliter) correlated very well with the titer of total IgG ELISA (in units per milliliter) (Figure 3). Ig4 was the sole antibody subclass present in 3 of 84 (4%) aPLA₂R-positive patients. In 4 of 84 (5%) patients with positive overall ELISA, IgG4 subclass was negative. IgG1 was present in two patients, one time combined with IgG3 and one time combined with IgG2. In one patient, only IgG2 was positive, and in the last patient, IgG2 was present below the normal threshold. Agreement of IgG subclass testing between IIFT and ELISA techniques was only moderate for IgG1, IgG2, and IgG3 (74%, 63%, and 71% overall agreement, respectively). In contrast, overall agreement for IgG4 positivity was fair with 89% concordance.

Remarkably, in aPLA₂R-positive patients, the level of aPLA₂R IgG4, when adjusted for fractional IgG excretion, also correlated well with baseline proteinuria ($n=52$; $r=0.768$, $P<0.01$).

Correlations with Outcome

Outcome data were available for 93% of patients ($n=109$) after a median follow-up of 54 months (range=2–277 months). During

follow-up, 41 (38%) patients had been treated with supportive therapy only, whereas 68 (62%) patients had received immunosuppressive therapy (various agents were used, such as cyclophosphamide, mycophenolate mofetil, rituximab, and adrenocorticotrophic hormone); 14 (13%) patients progressed to renal failure, whereas remission of proteinuria occurred in 77 (71%) patients some time during follow-up (38% of patients had partial remission, and 33% of patients had complete remission). Of these remissions, 49 (64%) remissions developed after immunosuppressive treatment, and 28 (36%) remissions were considered spontaneous remissions. Time to remission was significantly shorter in patients treated with immunosuppressive drugs (median=13 months [range=5–276 months] versus median=31 months [range=7–181 months], $P<0.01$) in patients with spontaneous remissions.

Comparing aPLA₂R-positive versus -negative patients, there was no difference between the percentages of patients that were treated with immunosuppressive drugs (63% versus 67%). Although remissions tended to occur slightly more often in the aPLA₂R-negative patients (83% versus 68%) and were more often spontaneous (33% versus 24% in aPLA₂R-positive patients), the differences were not statistically significant. Median time to remission did not differ between aPLA₂R-positive and -negative patients, and this conclusion also held when analysis was limited to patients treated with immunosuppressive agents.

Next, we analyzed the aPLA₂R-positive patients for evidence that the level of antibodies was correlated with outcome. Patients were divided in tertiles based on the ELISA titer. Renal failure tended to occur less frequently in patients in the lowest tertile of antibody titer. More importantly, there was a significant difference in the rate of spontaneous remissions, because only one spontaneous remission occurred in the patients with aPLA₂R titers in the highest tertile ($P<0.01$) (Table 3). Using IIFT, a lower incidence of spontaneous remissions in the category of patients with the highest aPLA₂R titer was also observed ($P=0.03$) (Table 4). Outcome was related to IgG subclass and titer. Specifically, when analyzing the data according tertiles of IgG4 antibody titer, spontaneous remissions were less likely to occur in patients with the highest titer of IgG4 antibodies (Supplemental Table 1A). Analysis of data according IgG3 or IgG1 subclass did not reveal significant differences (Supplemental Table 1, B and C). We separately analyzed

Table 3. Outcome in aPLA₂R antibody-positive patients ($n=79$): outcome in different tertiles of antibody titer (ELISA)

| Outcome | aPLA ₂ R=41–175 U/ml ($n=26$) | aPLA ₂ R=176–610 U/ml ($n=26$) | aPLA ₂ R>610 U/ml ($n=27$) | P Value |
|------------------------------------|--|---|---|---------|
| Partial remission | 11 (42%) | 8 (31%) | 11 (41%) | NS |
| Complete remission | 7 (27%) | 9 (35%) | 8 (30%) | NS |
| Renal failure | 1 (4%) | 3 (12%) | 5 (19%) | NS |
| Persistent proteinuria | 7 (27%) | 6 (23%) | 3 (11%) | NS |
| Spontaneous remission ^a | 10 (38%) | 8 (31%) | 1 (4%) | <0.01 |

Definitions of remission are in the text.

^aNo treatment with immunosuppressive agents.

Table 4. Outcome in aPLA₂R antibody-positive patients (n=79): outcome in different categories of antibody titer (IIFT)

| Outcome | aPLA ₂ R=1:10 or 1:32 (n=27) | aPLA ₂ R>1:100 (n=29) | aPLA ₂ R>1:100 (n=23) | P Value |
|------------------------------------|---|----------------------------------|----------------------------------|---------|
| Partial remission | 10 (37%) | 11 (38%) | 9 (39%) | NS |
| Complete remission | 6 (22%) | 10 (35%) | 8 (35%) | NS |
| Renal failure | 1 (4%) | 4 (14%) | 4 (17%) | NS |
| Persistent proteinuria | 10 (37%) | 4 (14%) | 2 (9%) | NS |
| Spontaneous remission ^a | 8 (30%) | 10 (35%) | 1 (4%) | 0.03 |

Definitions of remission are in the text.

^aNo treatment with immunosuppressive agents.

treatment response in relation to anti-PLA₂R titer in patients who were treated with immunosuppressive agents. Patients in the highest tertile of antibody titer more often needed immunosuppressive therapy (88% versus 54% and 48% of patients in the middle and lowest tertiles, respectively). Moreover, antibody levels predicted the response to immunosuppressive therapy defined as time from start therapy to remission, which was a median of 5 months (range=3–7 months) in the lowest tertile, 7 months (range=5–32 months) in the middle tertile, and 10 months (range=6–219 months) in the highest tertile ($P<0.01$).

DISCUSSION

We detected antibodies against PLA₂R in 74% of patients with iMN using either IIFT or ELISA. Our data underline the pathogenetic role of these antibodies, especially of the IgG4 subclass, given the relationship of antibody titer with baseline proteinuria and outcome.

We have used two different methodologies under tightly controlled conditions for the detection of aPLA₂R antibodies: a commercially available IIFT and a recently in-house-developed ELISA. Duplicate serum samples were shipped to each laboratory, and results were generated in a blinded fashion, with the data analyzed at an independent center. Although the standards used for both assays and the means of determining the threshold for negative/positive discrimination were different, the agreement between IIFT and ELISA was excellent, with an overall agreement of 94% ($\kappa=0.85$), which is quite remarkable. The protein sequence in both tests is the same; therefore, we expected different accessibility of the epitopes or affinity of the antibodies, because in IIFT, the antigen is presented on a cell membrane, albeit in a fixed configuration, whereas in ELISA, the antigen may adopt a different conformation when adsorbed to the plate surface. These findings suggest that aPLA₂R antibodies bind to a specific epitope that is highly conserved under different conditions. This finding is remarkable, because the aPLA₂R antibodies were detected using Western blotting technique and electrophoresis of glomerular extracts under nonreducing conditions, indicating that it is a conformational epitope.^{4,7}

In seven patients with discrepant results in IIFT and ELISA, a third assay was performed, namely the Western blot (WB)

assay (Supplemental Methods). The assay was performed under nonreducing conditions at a serum dilution of 1:10. In summary, four of five patients with positive IIFT staining and negative ELISA titers showed antibody positivity in the Western blot. One of two patients with negative IIFT staining and positive ELISA titer was also negative in WB, and the other patient was clearly positive (Supplemental Figure 2). In conclusion, results with WB were mostly, but not always, in line with the results of IIFT.

We included 117 patients with iMN of recent onset and nephrotic range proteinuria. In our cohort, the largest studied thus far, 74% (IIFT) and 72% (ELISA) were positive for aPLA₂R. In the literature, the reported prevalence of aPLA₂R antibodies in patients with iMN varies between 52% in a German study and 82% in a Chinese cohort.^{7,9} These differences may be explained by differences in ethnicity, technique of the assay, clinical characteristics of the included patients, or nature of the study.¹² The low prevalence rate of 52% was found in a cross-sectional study that used the IIFT test.⁹ The work by Hoxha *et al.*⁹ included patients with active as well as inactive disease, and in 48% of patients, no data on proteinuria were available.⁹ When limiting the analysis to patients with proteinuria >3.5 g/d, which likely reflects active disease, the percentage of patients with anti-PLA₂R antibodies was 66%.

The work by Qin *et al.*⁷ suggested that a more sensitive analysis may reveal an even higher prevalence. In their standard WB assay, 82% of patients were aPLA₂R-positive.⁷ However, when using less diluted patient serum and a higher concentration of detecting antibody, a low titer of anti-PLA₂R antibody was detectable in 10 of 11 apparently negative patients.⁷ The specificity of these findings was high, because low titers were not found in 20 healthy controls.⁷ In contrast, we have used a very sensitive ELISA technique, which detects a signal representing low antibody titers in normal controls. Therefore, it seems most unlikely that we have missed aPLA₂R-positive patients. Altogether, our data indicate that 70%–75% of recently presenting Caucasian patients with nephrotic syndrome and iMN have detectable aPLA₂R.

We were unable to find significant differences in baseline characteristics and outcome between aPLA₂R-positive and -negative patients. This finding is consistent with our view that the pathogenesis in these aPLA₂R-negative patients is different and not related to low, unmeasurable aPLA₂R titers, which should be reflected in less severe or early remitting

disease. It is likely that, in these aPLA₂R-negative patients, other antibodies and antigens are involved, leading to comparable clinical disease; examples were provided in recent studies.^{13–16}

We tested the clinical relevance of the antibodies by evaluating the correlation of antibody titers with proteinuria and outcome. We observed a weak but significant correlation between baseline proteinuria and aPLA₂R titers measured by ELISA, although significance was lost when using the data obtained with the IIFT assay. Additional analysis of our data provided strong additional support for the clinical relevance of the antibody levels. First, when limiting the analysis to the patients of the Dutch cohort, a significant correlation between aPLA₂R titer and proteinuria was noted both with ELISA and IIFT. In the Dutch cohort, data on proteinuria are less variable; these patients collected two sequential 24-hour urine samples, and mean values were used for the analysis. Moreover, in the Dutch patients, we also collected exactly timed urine samples under standardized conditions (patients resting quietly) and quantitated protein excretion. There was a significant correlation between aPLA₂R titer and protein excretion (ELISA, $r=0.374$, $P<0.01$).

Second, in patients with a nephrotic syndrome, significant quantities of Igs are lost in the urine. Therefore, serum levels do not necessarily reflect antibody production and exposure of the podocyte to IgG. Indeed, if we corrected serum aPLA₂R levels for urinary losses, all correlations became stronger. We admit that these adjustments, although plausible, only provide circumstantial evidence. Because proteinuria is factored in both the x and y variables, stronger correlations can be expected. Of note, when adjusting serum aPLA₂R titer for serum IgG concentration, similar significant correlations were noted (data not shown). The clinical relevance of aPLA₂R titers is also supported by our observation that aPLA₂R titers were related to outcome. Specifically, spontaneous remissions were very rarely seen in patients with highest aPLA₂R levels. This latter observation suggests that the level of antibody titer is correlated with severity of disease. We cannot exclude that the patients with low titers of anti-PLA₂R may be on the downward slope of their immunologic disease course and thus, are more likely to develop a spontaneous remission. However, we consider this possibility unlikely, because all serum samples were collected shortly after the initial diagnostic biopsy (median=2 months, maximum=6 months). Moreover, time to remission was relatively long (median=31 months) in patients who developed a spontaneous remission.

Few studies have addressed the clinical relevance of aPLA₂R antibody levels. In another collaborative study, we reported 14 aPLA₂R-positive patients with iMN and a nephrotic syndrome studied at baseline, at remission, and during relapse.⁶ In these patients, aPLA₂R antibodies were detected by a WB technique. There was a striking correlation between aPLA₂R titer and proteinuria when using both baseline data and all data. There was an association between aPLA₂R and clinical course, because antibodies disappeared in all but one patient during

remission and reappeared in all evaluated patients during relapse. A similar association was reported in the work by Beck *et al.*⁸ that evaluated the time course of anti-PLA₂R in relation to proteinuria and outcome in patients with iMN treated with rituximab. Equally, in this study, the decrease of anti-PLA₂R titer preceded the decrease of proteinuria and predicted outcome. The work by Kanigicherla *et al.*¹¹ measured anti-PLA₂R by ELISA. In their cross-sectional analysis, antibody positivity was related to disease activity, and in the patients with active disease, the titer of PLA₂R predicted outcome. An association between the titer of anti-PLA₂R and outcome was also suggested in the work by Qin *et al.*⁷ In patients with a low titer, the time to remission was considerably shorter (6.6 versus 14.5 months), and the likelihood of remission was higher (50% versus 30% at 12 months).⁷ Overall, these data show that the course of aPLA₂R in patients with iMN parallels the clinical course. Moreover, the levels of aPLA₂R correlate with proteinuria and outcome. This finding adds to the hypothesis that aPLA₂R antibodies, indeed, may be of pathogenetical and clinical relevance, although other antibody specificities might be associated.

We also evaluated the subclass of the aPLA₂R. Our data confirmed that IgG4 is the dominant subclass in most patients. However, levels of IgG4 aPLA₂R correlated with proteinuria only in an adjusted analysis. This finding may be explained by the fact that IgG4 is a negatively charged protein, and glomerular permselectivity changes preferentially, affecting the filtration of negatively charged proteins. Indeed, the ratio of the clearance of IgG and IgG4 decreased in patients with minimal change disease, compatible with increased filtration of IgG4.¹⁷ Still, we cannot exclude that these adjustments may cause an artificial correlation. We did, however, find a significant correlation between IgG4, but not IgG1 and IgG3, titers and the occurrence of spontaneous remissions. Most patients have IgG4 combined with other subclasses, 5%–10% of positive patients have only IgG4, and another 5%–10% of positive patients have no IgG4 at all. However, the fact that IgG4 is prevailing and that there is a correlation with proteinuria argues for a pathogenic role of IgG4. It has been suggested that IgG4, although not binding complement, may activate complement by binding mannose binding lectin.

Our study has several limitations. Although this study is the largest series studied so far, additional studies enrolling a greater number of patients should be performed to validate the established correlations. Because kidney biopsies were not available for study in most patients, one cannot exclude the fact that some patients were misclassified, because in a previous study, a few patients had deposited PLA₂R without circulating antibodies or conversely, aPLA₂R in serum without PLA₂R antigen in deposits.¹⁰

In conclusion, in a large, well phenotyped cohort of patients with iMN, aPLA₂R antibodies were measured with IIFT and ELISA, with excellent agreement between both assays. Prevalence of aPLA₂R antibodies was 72%–74%. Antibody titers correlated with baseline proteinuria. The suggestion that the

level of antibodies reflects severity of disease was supported by the observation that spontaneous remissions occurred significantly less frequently during follow-up in patients with high antibody titers. IgG4 was the dominant subclass in the majority of patients and correlated with the occurrence of spontaneous remissions as well. However, IgG4 antibodies are combined with other aPLA₂R Ig subclasses in most patients.

CONCISE METHODS

Patient Selection

We selected patients from three cohorts of patients with iMN (Dutch, French, and Manchester cohorts). Two cohorts (Dutch and French) have been described recently.⁵ In addition, we included additional patients prospectively studied in France (Hopital Tenon, Paris, France) and the United Kingdom (Manchester). In all patients, the diagnosis was established by renal biopsy, and secondary causes were excluded according to local routine clinical workup. For this study, we only included patients in whom a stored baseline serum sample was available and collected within 6 months from the date of renal biopsy. We excluded patients who had been treated with immunosuppressive drugs before baseline and patients with non-nephrotic proteinuria. For all patients, baseline data on serum creatinine concentration and proteinuria were available. More detailed baseline data were available for the Dutch cohort as described.¹⁸

Specifically, all Dutch patients were studied under standardized conditions, with collection of two 24-hour urine samples for measurement of total proteinuria and timed urine samples for measurement of urine low and high molecular proteins. All patients were prospectively followed, and clinical outcome data were available for most patients. Available sera were exchanged and shipped for measurement of aPLA₂R by IIFT (by H.D.) and ELISA (by P.E.B.) within our groups.

Detection of aPLA₂R Antibodies and IgG Subclasses by IIFT

Anti-PLA₂R-specific autoantibody titers were measured using IIFT (IIFT Mosaic; EUROIMMUN AG, Lübeck, Germany). The details of this technique, which uses transfected HEK 293 cells that express PLA₂R and nontransfected cells as controls, have been described previously.^{9,10} Negativity of aPLA₂R was defined as absence of detectable antibodies at serum dilution of 1/10. Antibody positivity was defined as positive staining at serum dilutions of 1/10 or higher. In aPLA₂R-positive patients, quantitative measurements were performed using different serum dilutions (1/10, 1/100, and 1/1000). A strong staining at a dilution of 1/1000 was defined as 1/3200.

In addition, subtype specificity of the antibodies was assessed in aPLA₂R-positive patients by qualitative IIFT. To this end, after incubation with serum, slides were incubated with monoclonal antihuman subclass-specific IgG antibodies commercially provided by Margaret Goodall, University of Birmingham and revealed by Alexa-coupled anti-mouse secondary antibody (Molecular Probes). Again, positivity for an IgG subclass was defined as positive staining at serum dilution of 1/10.

Detection of aPLA₂R by ELISA

The full-length protein sequence (180 kD) was used to coat ELISA plates at 0.125 µg/ml in sodium bicarbonate buffer (pH 9.6) for 18 hours. The PLA₂R protein construct was the full extracellular sequence (amino acids 21–1397; containing N-terminal cysteine-rich domain, Fibronectin Type II domain, and C-type lectin domain 1–8) devoid of the transmembrane domain (amino acids 1398–1418) and cytoplasmic domain (amino acids 1419–1463). Plates were blocked for 1 hour with SuperBlock (Thermosystems) and kept at 4°C until use (within 3 days). Patient serum diluted 1:100 in superblock containing 0.1% Tween 20 was added in duplicate 100-µl aliquots to the ELISA plate, which also contained a standard dilution series of standard-2 (STD2) and quality control 1 (QC1) in duplicate wells (a between-plate quality control sample). After 2 hours incubation at room temperature on a plate shaker, the plates were washed thoroughly (eight times) with PBS plus 0.1% Tween 20. Anti-human IgG-horseradish peroxidase conjugate (HRP; Jackson Laboratories) diluted 1:25,000 in Superblock was added (100 µl per well) and incubated for 2 hours as before. After washing as before, enzyme substrate tetramethylbenzidine (Sigma) was added and developed for 10 minutes, and the reaction was stopped with 0.5 M H₂SO₄. The plates were read at 450 nm, standard curves were plotted using Softmax software, and values were assigned to samples. Samples that were off scale were diluted 1:1000 to 1:10,000 and reanalyzed.

Standard STD2 was allocated a value of 99,000 U/ml and was a pool of high-titer samples ($n=10$) that had been microfuged and filtered through 0.22-µm membrane, aliquoted, and stored at -80°C. For each ELISA plate, a dilution series covering the range from 3000 to 12.3 U/ml was applied to the plate.

Normal Range

Seventy-three serum samples from healthy individuals (mean age=41 ± 10 years) were used to define the normal range. Using mean + 3 SD of the normal range, we report a threshold above 40 U/ml as positive.

Quality Control

The assay was monitored for between-batch variation by incorporating an aliquot of the QC sample in duplicate on each plate. The QC sample was a pool of iMN sera ($n=10$) with borderline positivity (53 U/ml) that had been processed and stored in the same manner as STD2. Results from 22 different plate batches show a coefficient of variation of 17.8%. Samples applied to the same plate report less than 8% variation.

PLA₂R ELISA for IgG Subclasses

The assay for IgG subclass aPLA₂R was similar to the assay described above, and each sample (dilution of 1:100) was applied to a set of four plates. The standard curve for each set of plates used myeloma IgG1, IgG2, IgG3, or IgG4 (the binding site) coated in the standard wells covering the range of 250–8 ng/ml. Anti-IgG-HRP was substituted in the second incubation with sheep anti-IgG subclass (G1, G2, G3, or G4) HRP conjugate (the binding site) at dilutions of 1:16,000, 1:8000, 1:32,000, and 1:16,000, respectively, in each of the four plates. The plates were developed and read as in the total aPLA₂R

assay. A standard curve for the subclass concentration was plotted on each plate, and test sample concentrations were calculated from the curve and expressed as nanograms per milliliter aPLA₂R. Subclass aPLA₂R levels were also measured in healthy controls ($n=33$), providing the normal values for the assays. Positivity for IgG subclass was defined as a value more than mean + 3 SD (>8.6 ng/ml for IgG1, >36.5 ng/ml for IgG2, >2.3 ng/ml for IgG3, and >4.9 ng/ml for IgG4).

Definitions and Calculations

We assessed the concordance between the IIFT and ELISA tests for detecting aPLA₂R. IIFT testing was performed in Paris, France (laboratory of H.D. and P.R.), and ELISA testing in the same samples was performed in Manchester, United Kingdom (laboratory of P.E.B.). Both laboratories were not aware of the other's test results. Results were combined with clinical data and analyzed in Nijmegen, The Netherlands (by J.M.H. and J.F.W.). In absence of a reference standard, agreement between both tests is reported as overall percentage of agreement and Cohen's κ value of agreement. In additional analyses, where we compared aPLA₂R-positive with -negative patients, only those patients with results of the two tests concordant were considered positive.

Baseline clinical data were available for all three cohorts. Proteinuria data were reported as grams per day in British patients and gram per 10 mmol creatinine in French patients. For Dutch patients, both 24-hour collections and protein/creatinine ratios were available. To be able to perform analyses for the total cohort of patients, proteinuria per 10 mmol creatinine in the French cohort was re-expressed as grams per day by multiplying with a factor of 1.15 in men and 1.00 in women (based on observed mean daily urinary creatinine excretion).¹⁸ Estimated GFR (eGFR) at baseline was estimated by applying the Modification of Diet in Renal Disease 4 (MDRD4) formula.

Correlations between aPLA₂R titers (measured by both IIFT and ELISA) and clinical parameters were assessed. Because antibody titer itself could be influenced by the magnitude of proteinuria (by subsequent loss of antibodies in the urine), we repeated these analyses for titers adjusted for fractional IgG excretion (titer multiplied by fractional IgG excretion; data were available in Dutch cohort only).

Outcome data were available in most patients. Partial remission was defined as proteinuria <3.5 g/d with a decrease of proteinuria $>50\%$ from baseline and stable renal function. Remission was considered complete when protein excretion was <0.2 g/d with stable renal function. Furthermore, remissions were classified as spontaneous if occurring without the use of immunosuppressive agents any time during follow-up.

Renal failure was defined as a sustained increase of serum creatinine $>50\%$ from baseline.

Statistical Analyses

For descriptive statistics, data are presented as mean (\pm SD) or median (range) when appropriate. The correlation between several parameters (nonparametric distributions) was analyzed by Spearman's rank coefficient of correlation; t , Mann-Whitney U, and Kruskal-Wallis tests were used for comparison between groups. Cumulative probabilities

of an event (e.g., remission or renal failure) were estimated according to Kaplan and Meier tests. Generalized Wilcoxon (Breslow) tests were used to compare the interval for the appearance of these events (e.g., time to remission).

All statistics were performed using PASW (SPSS) software, version 18.0.2 (IBM, Armonk, NY). Differences were considered significant with P value <0.05 .

ACKNOWLEDGMENTS

For the Dutch cohort, we acknowledge the physicians, research nurses, and patients who contributed to the studies from the following hospitals: Jeroen Bosch Hospital, 's-Hertogenbosch, Canisius Wilhelmina Hospital, Nijmegen, Maxima Medical Center, Veldhoven, Laurentius Hospital, Roermond, Hospital Gelderse Vallei, Ede, Hospital Rijnstate, Arnhem, Franciscus Hospital, Roosendaal, St. Elisabeth Hospital, Tilburg, Gelre Hospitals, Apeldoorn, Slingeland Hospital Doetinchem, Hospital Bernhoven, Veghel, Catharina Hospital, Eindhoven, and Amphia Hospital, Breda. For the French cohort, we acknowledge Ms. Karine Dahan for patients' care. We acknowledge the physicians, research nurses, and patients who contributed. We thank the UK DNA Banking Network archive (funded by the Medical Research Council and Kidney Research UK at the Centre for Integrated Genomic Medical Research, University of Manchester) for iMN sample management.

J.M.H. and J.F.W. are supported by Dutch Kidney Foundation Grants NSN OW8 and KJPB 11.021. H.D. is the recipient of a Contrat d'Interface from Assistance Publique-Hôpitaux de Paris. H.D. and P. R. are supported by an Agences de la Biomédecine Grant, Agence Nationale pour la Recherche Grant ANR-07-Physio-016-01, Co-ordination Theme 1 (Health) of the European Community's 7th Framework Program Grant HEALTH-F2-2007-201590, and a Fondation pour la Recherche Médicale Grant. C.D.S. and P.E.B. acknowledge support from the Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, and Kidneys for Life Charity (505256).

DISCLOSURES

None.

REFERENCES

1. Cattran DC: Management of membranous nephropathy: When and what for treatment. *J Am Soc Nephrol* 16: 1188–1194, 2005
2. du Buf-Vereijken PW, Branten AJ, Wetzels JF: Idiopathic membranous nephropathy: Outline and rationale of a treatment strategy. *Am J Kidney Dis* 46: 1012–1029, 2005
3. Glasscock RJ: Secondary membranous glomerulonephritis. *Nephrol Dial Transplant* 7[Suppl 1]: 64–71, 1992
4. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. *N Engl J Med* 361: 11–21, 2009

5. Stanescu HC, Arcos-Burgos M, Medlar A, Bockenbauer D, Kottgen A, Dragomirescu L, Voinescu C, Patel N, Pearce K, Hubank M, Stephens HA, Laundry V, Padmanabhan S, Zawadzka A, Hofstra JM, Coenen MJ, den Heijer M, Kiemeny LA, Bacq-Daian D, Stengel B, Powis SH, Brenchley P, Feehally J, Rees AJ, Debiec H, Wetzels JF, Ronco P, Mathieson PW, Kleta R: Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. *N Engl J Med* 364: 616–626, 2011
6. Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ: Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. *Clin J Am Soc Nephrol* 6: 1286–1291, 2011
7. Qin W, Beck LH Jr, Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z: Anti-phospholipase A₂ receptor antibody in membranous nephropathy. *J Am Soc Nephrol* 22: 1137–1143, 2011
8. Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, Cosio FG, Cattran DC, Salant DJ: Rituximab-induced depletion of anti-PLA₂R autoantibodies predicts response in membranous nephropathy. *J Am Soc Nephrol* 22: 1543–1550, 2011
9. Hoxha E, Harendza S, Zahner G, Panzer U, Steinmetz O, Fechner K, Helmchen U, Stahl RA: An immunofluorescence test for phospholipase-A₂-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. *Nephrol Dial Transplant* 26: 2526–2532, 2011
10. Debiec H, Ronco P: PLA₂R autoantibodies and PLA₂R glomerular deposits in membranous nephropathy. *N Engl J Med* 364: 689–690, 2011
11. Kanigicherla DKA, Brenchley PE, Venning M, Poulton KV, McKenzie EA, Gummadova JO, Short CD: Association of anti-PLA₂R with disease activity and outcome in idiopathic membranous nephropathy [abstract]. *J Am Soc Nephrol* 22: 33A, 2011
12. Hofstra JM, Wetzels JF: Anti-PLA₂R antibodies in membranous nephropathy: Ready for routine clinical practice? *Neth J Med* 70: 109–113, 2012
13. Prunotto M, Carnevali ML, Candiano G, Murtas C, Bruschi M, Corradini E, Trivelli A, Magnasco A, Petretto A, Santucci L, Mattei S, Gatti R, Scolari F, Kador P, Allegri L, Ghiggeri GM: Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. *J Am Soc Nephrol* 21: 507–519, 2010
14. Bruschi M, Carnevali ML, Murtas C, Candiano G, Petretto A, Prunotto M, Gatti R, Argentiero L, Magistroni R, Garibotto G, Scolari F, Ravani P, Gesualdo L, Allegri L, Ghiggeri GM: Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens. *J Proteomics* 74: 2008–2017, 2011
15. Debiec H, Guignonis V, Mougenot B, Decobert F, Haymann JP, Bensman A, Deschênes G, Ronco PM: Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. *N Engl J Med* 346: 2053–2060, 2002
16. Debiec H, Lefeu F, Kemper MJ, Niaudet P, Deschênes G, Remuzzi G, Ulinski T, Ronco P: Early-childhood membranous nephropathy due to cationic bovine serum albumin. *N Engl J Med* 364: 2101–2110, 2011
17. Buis B, Wever PC, Koomen GC, van Acker BA, Groothoff JW, Krediet RT, Arisz L: Clearance ratios of amylase isoenzymes and IgG subclasses: Do they reflect glomerular charge selectivity? *Nephron* 75: 444–450, 1997
18. van den Brand JA, Hofstra JM, Wetzels JF: Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy. *Clin J Am Soc Nephrol* 6: 2846–2853, 2011

This article contains supplemental material online at <http://jasn.asnjournals.org/lookup/suppl/doi:10.1681/ASN.2012030242/-/DCSupplemental>.